The impact of different doses of antithymocyte globulin conditioning on immune reconstitution upon hematopoietic stem cell transplantation.

[1]  Yu Wang,et al.  Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study , 2019, BMC Medicine.

[2]  Gaohui Yang,et al.  Immune recovery after in vivo T‐cell depletion myeloablative conditioning hematopoietic stem cell transplantation in severe beta‐thalassemia children , 2019, European journal of haematology.

[3]  J. Abrahamsson,et al.  Use of multivariate immune reconstitution patterns to describe immune reconstitution after allogeneic stem cell transplantation in children. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  M. Schilham,et al.  Differential Elimination of Anti-Thymocyte Globulin of Fresenius and Genzyme Impacts T-Cell Reconstitution After Hematopoietic Stem Cell Transplantation , 2019, Front. Immunol..

[5]  J. Ritz,et al.  Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  U. Salmenniemi,et al.  Early CD8+-recovery independently predicts low probability of disease relapse but also associates with severe GVHD after allogeneic HSCT , 2018, PloS one.

[7]  S. Park,et al.  Role of thymoglobulin in matched sibling allogeneic hematopoietic stem cell transplantation with busulfan and fludarabine conditioning in myeloid malignanicies , 2018, Bone Marrow Transplantation.

[8]  L. Notarangelo,et al.  Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study. , 2017, Blood.

[9]  Shunqing Wang,et al.  [Value of CD3+CD4+ T Cell Count in Prediction of Viral Infection after Hematopoietic Stem Cell Transplantation in Patients Severe Aplastic Anemia]. , 2017, Zhongguo shi yan xue ye xue za zhi.

[10]  Yu-Hong Chen,et al.  Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long‐term outcomes of a prospective randomized trial , 2017, Cancer.

[11]  C. Schmoor,et al.  Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. , 2017, The Lancet. Haematology.

[12]  H. Reichardt,et al.  Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines , 2017, Annals of Hematology.

[13]  J. Esteve,et al.  Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation , 2017, Haematologica.

[14]  J. Goldberg,et al.  Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant , 2017, Leukemia & lymphoma.

[15]  Yu Wang,et al.  Rapid Recovery of CD3+CD8+ T Cells on Day 90 Predicts Superior Survival after Unmanipulated Haploidentical Blood and Marrow Transplantation , 2016, PloS one.

[16]  N. Kadowaki,et al.  Antilymphocyte Globulin for Chronic Graft-versus-Host Disease. , 2016, The New England journal of medicine.

[17]  Yu Wang,et al.  Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study , 2016, Clinical Cancer Research.

[18]  T. Panzarella,et al.  Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. , 2016, The Lancet. Oncology.

[19]  M. Guo,et al.  Effects of CIK on hypoxia inducible factor-1α and T-cell subsets on colon 26 cancer xenograft mice , 2016, Oncology letters.

[20]  Giuseppe Milone,et al.  Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. , 2016, The New England journal of medicine.

[21]  Yu Wang,et al.  Differential impact of two doses of antithymocyte globulin conditioning on lymphocyte recovery upon haploidentical hematopoietic stem cell transplantation , 2015, Journal of Translational Medicine.

[22]  C. Lengerke,et al.  Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation , 2015, Bone Marrow Transplantation.

[23]  F. Baron,et al.  Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation , 2015, PloS one.

[24]  Yu Wang,et al.  Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. , 2015, Blood.

[25]  T. Egberts,et al.  Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. , 2015, The Lancet. Haematology.

[26]  C. Hofmeister,et al.  Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant , 2015, Leukemia & lymphoma.

[27]  H. Einsele,et al.  Effect of ATG‐F on B‐cell reconstitution after hematopoietic stem cell transplantation , 2015, European journal of haematology.

[28]  S. Siitonen,et al.  Impact of very early CD4+/CD8+ T cell counts on the occurrence of acute graft‐versus‐host disease and NK cell counts on outcome after pediatric allogeneic hematopoietic stem cell transplantation , 2015, Pediatric blood & cancer.

[29]  R. Porcher,et al.  Long-term immune reconstitution and infection burden after mismatched hematopoietic stem cell transplantation. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  L. Xu,et al.  Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial , 2014, Bone Marrow Transplantation.

[31]  R. Bouabdallah,et al.  Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[32]  F. Locatelli,et al.  Human Cytomegalovirus Infection Promotes Rapid Maturation of NK Cells Expressing Activating Killer Ig–like Receptor in Patients Transplanted with NKG2C−/− Umbilical Cord Blood , 2014, The Journal of Immunology.

[33]  P. Ljungman,et al.  A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors , 2013, Clinical transplantation.

[34]  H. Deeg,et al.  Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  D. Maloney,et al.  Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. , 2012, Cytotherapy.

[36]  A. Nademanee,et al.  A phase II study of sirolimus, tacrolimus, and rabbit anti-thymocyte globulin as graft-versus-host prophylaxis after unrelated-donor peripheral blood stem cell transplant , 2012, Bone Marrow Transplantation.

[37]  B. Esterni,et al.  The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT , 2012, Bone Marrow Transplantation.

[38]  A. Gratwohl,et al.  Lymphocyte subset recovery and outcome after T-cell replete allogeneic hematopoietic SCT , 2011, Bone Marrow Transplantation.

[39]  D. Porter,et al.  Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. , 2011, Blood.

[40]  J. Bourhis,et al.  Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire , 2010, Leukemia.

[41]  M. Robin,et al.  Long-term immune deficiency after allogeneic stem cell transplantation: B-cell deficiency is associated with late infections , 2010, Haematologica.

[42]  E. Thiel,et al.  Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion , 2010, International journal of hematology.

[43]  J. Byrd,et al.  Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[44]  E. Thiel,et al.  The type of ATG matters -- natural killer cells are influenced differentially by Thymoglobulin, Lymphoglobulin and ATG-Fresenius. , 2007, Transplant immunology.

[45]  L. Notarangelo,et al.  Long-term immune reconstitution and clinical outcome after stem cell transplantation for severe T-cell immunodeficiency. , 2007, The Journal of allergy and clinical immunology.

[46]  J. P. McCoy,et al.  Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. , 2007, Blood.

[47]  M. Zand.  B-cell activity of polyclonal antithymocyte globulins. , 2006, Transplantation.

[48]  D. Blaise,et al.  Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. , 2003, Blood.

[49]  H. Kirchner,et al.  Immune reconstitution and production of intracellular cytokines in T lymphocyte populations following autologous peripheral blood stem cell transplantation , 2001, Bone Marrow Transplantation.

[50]  J. Revillard,et al.  MECHANISMS INVOLVED IN ANTITHYMOCYTE GLOBULIN IMMUNOSUPPRESSIVE ACTIVITY IN A NONHUMAN PRIMATE MODEL 1 , 2001, Transplantation.

[51]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[52]  Heidi Chen,et al.  Optimizing Antithymocyte Globulin Dosing for Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Based on Recipient Absolute Lymphocyte Count. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[53]  S. Zimin.  Allogeneic hematopoietic stem cell transplantation in the treatment of hematological malignancies , 2004 .